{"id":69226,"date":"2012-02-07T08:02:48","date_gmt":"2012-02-07T08:02:48","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/snapshot-for-ishares-nasdaq-biotechnology-index-fund-ibb.php"},"modified":"2024-08-17T15:54:41","modified_gmt":"2024-08-17T19:54:41","slug":"snapshot-for-ishares-nasdaq-biotechnology-index-fund-ibb","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/snapshot-for-ishares-nasdaq-biotechnology-index-fund-ibb.php","title":{"rendered":"Snapshot for iShares Nasdaq Biotechnology Index Fund (IBB)"},"content":{"rendered":"<p>Fund Profile &amp; Information for IBB        <\/p>\n<p class=\"profile_no_margin\">      iShares Nasdaq Biotechnology Index Fund is an exchange-traded      fund incorporated in the USA. The Fund&#039;s objective seeks      investment results that correspond to the performance of the      Nasdaq Biotechnology Index. The Fund will concentrate its      investments in companies primarily engaged in using      biomedical research for the discovery or development of new      treatments or cures for human disease.    <\/p>\n<p>                                                      Inception Date:                                      2001-02-09                                      Telephone:                                      1-415-597-2000                                                          Managers:                                      GREG SAVAGE                                                          Web Site:                                      <a href=\"http:\/\/www.ishares.com\" rel=\"nofollow\">http:\/\/www.ishares.com<\/a>                                                      Fundamentals for IBB                                NAV                          (on 2012-02-06) 121.9103                                      Assets (M)                          (on 2012-01-31) 1,683.8850                                      Shares out (M)                          14.15                                      Market Cap (M)                          1,724.74                                      % Premium                          -0.02                                      Average 52-Week % Premium                          -0.0079                                      Fund Leveraged                          N                                Dividends for IBB                                Dividend Type                          Income                                      Dividend Frequency                          Quarter                                      Last Dividend Net                          -                                      Dividend Yield (ttm)                          0.0119                                Performance for IBB                                1-Month                          +13.69%                          1-Year                          +29.48%                                      3-Month                          +27.00%                          3-Year                          +18.07%                                      Year To Date                          +16.81%                          5-Year                          +9.08%                                      Expense Ratio                          0.48                                                Top Fund Holdings for IBB    Filing Date: 02\/03\/2012                                        Amgen Inc                                2,016,922                                139,732,356                                8.256%                                                Alexion Pharmaceuticals Inc                                1,415,274                                111,629,737                                6.596%                                                Gilead Sciences Inc                                1,906,869                                104,296,200                                6.163%                                                Celgene Corp                                1,418,932                                103,880,012                                6.138%                                                Regeneron Pharmaceuticals Inc                                975,578                                944,944,858                                5.583%                                                Biogen Idec Inc                                685,802                                83,585,548                                4.939%                                                Teva Pharmaceutical Industries                                1,771,061                                80,955,198                                4.783%                                                Perrigo Co                                668,139                                62,577,899                                3.698%                                                Vertex Pharmaceuticals Inc                                1,460,207                                53,706,413                                3.173%                                                Mylan Inc\/PA                                2,187,785                                49,093,895                                2.901%<\/p>\n<p>More here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.bloomberg.com\/quote\/IBB:US\" title=\"Snapshot for iShares Nasdaq Biotechnology Index Fund (IBB)\" rel=\"noopener\">Snapshot for iShares Nasdaq Biotechnology Index Fund (IBB)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fund Profile &amp; Information for IBB iShares Nasdaq Biotechnology Index Fund is an exchange-traded fund incorporated in the USA. The Fund&#039;s objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/snapshot-for-ishares-nasdaq-biotechnology-index-fund-ibb.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-69226","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/69226"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=69226"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/69226\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=69226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=69226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=69226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}